2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
4 August 2020Portfolio NewsRibometrix Further Expands Leadership with Appointment of Barclay "Buck" Phillips as Chief Operating Officer and Chief Financial Officer- 4 August 2020Portfolio NewsCatabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis
23 July 2020Portfolio NewsXilio Therapeutics Appoints Paul J. Clancy to its Board of Directors- 20 July 2020SV NewsBritish Patient Capital commits $65m to SV Health Investors, to invest in life-changing biotechnology companies
6 July 2020Portfolio NewsAVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials- 23 June 2020Portfolio NewsSV Health Investors notes Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics
23 June 2020Portfolio NewsBicycle Therapeutics Appoints Sir Keith Peters as Chairman of Its Scientific Advisory Board
23 June 2020Portfolio NewsAlchemab Therapeutics among three companies that comprise the inaugural funding cycle of Illumina Accelerator Cambridge UK- 22 June 2020Portfolio NewsDeciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
- 17 June 2020Portfolio NewsXilio Therapeutics Appoints Daniel S. Lynch as Chair of Board of Directors
- 11 June 2020Portfolio NewsX4 Pharmaceuticals Promotes Renato Skerlj, Ph.D., to Chief Scientific Officer
- 8 June 2020Portfolio NewsDeciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK™ (ripretinib) in The Lancet Oncology
